A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

Glioblastoma Clinical Trial

Official title:

A Phase 1/2 Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02750891
• Other study ID #: DB601001
• Secondary ID: JapicCTI-163216
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: April 2016
• Est. completion date: January 2020

Study information

• Verified date: April 2022
• Source: Sumitomo Pharma Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1/2, uncontrolled, open-label, multicenter study in patients with recurrent and relapsed diffuse intrinsic pontine glioma, glioblastoma, or grade III or IV glioma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: January 2020
• Est. primary completion date: January 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 19 Years

Eligibility

Inclusion Criteria:

1. Patients meeting any of the conditions a) to c) below:

1. Have a diagnosis of diffuse intrinsic pontine glioma on the basis of imaging findings on magnetic resonance imaging (MRI) and clinical course

2. Have histologically or cytologically confirmed glioblastoma

3. Not meeting a) and b) above, but have histologically or cytologically confirmed grade III or IV glioma

2. Patients who will be able to be hospitalized from the initial dose of DSP-7888 until the end of the post-initial dose observation (In Phase 1 part only, patients may be permitted to have a temporary overnight leave during the hospitalization.)

3. Patients aged < 20 years at the time of informed consent

4. Patients for whom either the legally acceptable representative or the patient (if aged = 16 years) have provided written voluntary consent to participation in this study after fully receiving and understanding the information about this study, including study objectives, contents, expected pharmacological actions and effects, and foreseeable risks

5. Patients for whom standard therapy failed or no standard therapy is established

6. Diffuse intrinsic pontine glioma patients must received radiotherapy-based treatment or chemotherapy (if radiotherapy is not indicated) at least one cycle and subsequently had tumor enlargement accompanied by tumor-related symptomatic worsening (except for worsening due to dose reduction of steroid therapy for brain edema)

7. Glioblastoma patients and grade III or IV glioma patients must had radiologically evident tumor re-enlargement or recurrence

8. Patients with an ECOG PS score of 0 to 2 at enrollment. Patients with a PS score of 3 or 4 due to neurological symptoms associated with the primary disease may be eligible if appropriate in the opinion of the investigator or subinvestigator.

9. Patients with a life expectancy of 2 months (60 days)

10. Patients with a HLA type of HLA-A*24:02 or A*02:01/06

11. Patients with adequate major organ functions meeting the following criteria on the basis of laboratory data within 28 days before enrollment:

Neutrophil count: 1000/µL Platelet count: 5.0 ×104/µL Hemoglobin: 9.0 g/dL Serum creatinine: 2-fold the upper limit of the normal range of the study site (ULN) Total bilirubin: 2-fold the ULN AST, ALT: 3-fold the ULN

12. Female patients of childbearing potential must have a negative pregnancy test within 4 weeks (28 days) before enrollment

13. Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use appropriate contraception from the time of consent until 180 days after the last dose of the study drug to avoid pregnancy

Exclusion Criteria:

1. Patients with grade 3 infection according to the CTCAE v4.0

2. Patients with a positive test result for HIV antibody, HBs antigen, or HCV antibody

3. Patients with multiple or disseminated primary lesions (Multiple nodules in the same tumor cavity will be acceptable.)

4. Patients with other malignancies

5. Patients with significant diseases at enrollment that may affect study treatment, such as New York Heart Association (NYHA) Functional Class III or IV heart disease, CTCAE v4.0 grade 3 arrhythmia, angina pectoris, abnormal electrocardiogram findings, interstitial pneumonia or pulmonary fibrosis

6. Patients with uncontrollable complications

7. Patients who underwent allogeneic hematopoietic stem cell transplant

8. Patients who received any of the following treatments within the specified period before enrollment

• Nitrosoureas, mitomycin C: <42 days

• Chemotherapy (including molecular-targeted drugs), radiotherapy: <21 days

• Surgery, blood transfusion, erythropoiesis-stimulating drugs, endocrine therapy, immunotherapy (including biological response modifier [BRM] therapy): <14 days

9. Pregnant or breastfeeding women

10. Patients with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease, or patients who require long-term systemic steroid therapy (excluding therapy given on a PRN basis). However, steroid therapy for brain edema (prednisolone-equivalent dose of 30 mg/m2) and steroid replacement therapy at a physiologic dose will be acceptable.

11. Patients with any ongoing CTCAE v4.0 grade 2 adverse effects of prior treatment (excluding alopecia and phlebitis)

12. Patients who received any other investigational product or post-marketing study drug within 4 weeks (28 days) before enrollment

13. Patients with a history of allergy to any oil-based agents

14. Patients who previously received DSP-7888-containing WT1 peptide, or WT1 immunotherapy

15. Patients who are inappropriate for participation in the study for other reasons in the opinion of the investigator or subinvestigator

Related Conditions & MeSH terms

• Diffuse Intrinsic Pontine Glioma
• Glioblastoma
• Glioma

Intervention

Drug:
• DSP-7888
Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks

Locations

Country	Name	City	State
Japan	Hiroshima University Hospital	Hiroshima
Japan	National Hospital Organization Nagoya Medical Center	Nagoya	Aichi
Japan	Osaka City General Hospital	Osaka
Japan	National Center for Child Health and Development	Setagaya	Tokyo
Japan	Osaka University Hospital	Suita	Osaka
Japan	Kanagawa Children's Medical Center	Yokohama	Kanagawa

Sponsors (1)

Lead Sponsor	Collaborator
Sumitomo Pharma Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DLT (dose-limiting toxicity)	Safety and tolerability assessed by dose-limiting toxicity (DLT)	4 weeks
Primary	Overall Survival (OS)	Participants follow-up for overall survival will occur. Maximum follow-up time is 2 year after the initial administration of the last subject.	24 months
Secondary	Overall Response Rate(ORR)	Antitumor effect as assessed according to the Response Assessment in Neuro-Oncology (RANO) criteria	6 months
Secondary	Progression-free survival (PFS)		6 months
Secondary	adverse events (AEs)	Safety and tolerability assessed by adverse events (AEs)	12 months
Secondary	serious adverse events (SAEs)	Safety and tolerability assessed by serious adverse events (SAEs)	12 months
Secondary	DTH (delayed-type hypersensitivity)	Explore efficacy related biomarkers assessed by delayed-type hypersensitivity (DTH) reactions to WT1 peptide	6 months
Secondary	WT1 peptide-specific CTL-induction activity	Explore efficacy related biomarkers assessed by WT1 peptide-specific CTL-induction activity.	6 months
Secondary	expression of WT1 in biopsy tissues	Explore efficacy related biomarkers assessed in biopsy tissues	6 months
Secondary	expression of HLA in biopsy tissues	Explore efficacy related biomarkers assessed in biopsy tissues	6 months
Secondary	expression of PD-L1 in biopsy tissues	Explore efficacy related biomarkers assessed in biopsy tissues	6 months